Last Two Of Three Big Inclisiran Studies Boosts The Medicines Co.

 
• By Mandy Jackson

Filings for the twice-yearly anti-PCSK9 injection under a partnership with Alnylam are on track, including a fourth quarter submission in the US. Detailed ORION-9 and ORION-10 data will be presented at AHA in November.

GoldKeyInPuzzle_1200x675
The Medicines Co. unlocked the last two sets of Phase III data for inclisiran. • Source: Shutterstock

More from Clinical Trials

More from R&D